Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 8/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289980 | 1.00 | USP19 (0.38) | USP19HCRTR1HCRTR2SMN1; SMN2CA1 | |
| SCHEMBL13705409 | 0.94 | USP19 (0.36) | USP19HCRTR1HCRTR2REN | |
| SCHEMBL4290281 | 0.92 | USP19 (0.37) | USP19HCRTR2CA1CA2CA4 | |
| SCHEMBL4293974 | 0.92 | USP19 (0.37) | USP19HCRTR2CA1CA2CA4 | |
| SCHEMBL4285511 | 0.92 | USP19 (0.37) | USP19HCRTR1HCRTR2CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL4291249 | 0.91 | USP19 (0.34) | USP19HCRTR1HCRTR2REN | |
| SCHEMBL13705388 | 0.91 | CA1 (0.40) | USP19HCRTR1HCRTR2CA1CA2 | |
| SCHEMBL13341800 | 0.91 | CA1 (0.40) | USP19HCRTR1HCRTR2CA1CA2 | |
| SCHEMBL4285554 | 0.91 | CA1 (0.40) | USP19HCRTR1HCRTR2CA1CA2 | |
| SCHEMBL13705374 | 0.91 | CA1 (0.40) | USP19HCRTR1HCRTR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP19 1993/4885HCRTR1 3147/4885HCRTR2 3136/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP19 1993/4885HCRTR1 3147/4885HCRTR2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.